Abeona Therapeutics Inc. (ABEO) News
Filter ABEO News Items
ABEO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABEO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ABEO News From Around the Web
Below are the latest news stories about ABEONA THERAPEUTICS INC that investors may wish to consider to help them evaluate ABEO as an investment opportunity.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 30, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in t |
Owning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO),Key Insights Significantly high institutional ownership implies Abeona Therapeutics' stock price is sensitive to their... |
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ... |
ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Resubmission Accepted; PDUFA Date of April 29, 2025 On November 12, 2024, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. FDA has accepted the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) and set a PDUFA target action date of April 29, 2025. The resubmission of the |
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...Abeona Therapeutics Inc (ABEO) navigates regulatory hurdles and competition while preparing for the commercial launch of its innovative therapy. |
Abeona Therapeutics: Q3 Earnings SnapshotCLEVELAND (AP) — Abeona Therapeutics Inc. ABEO) on Thursday reported a loss of $20.3 million in its third quarter. On a per-share basis, the Cleveland-based company said it had a loss of 42 cents. |
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesFDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commercialization of pz-cel in 2025; Builds momentum with payor discussions and target treatment centers CLEVELAND, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the |
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis BullosaFDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona’s resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescr |
Abeona Therapeutics® Announces Participation in November Investor ConferencesCLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024: Truist Securities BioPharma Symposium: Investor meetings on Thursday, November 7, 2024.Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024 at 4:10 p.m. ET and investor meetings. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona |
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug AdministrationCLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA or Agency) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). “We have worked closely with the FDA in preparing for the pz-cel BLA resubmis |